RedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 2020

TEL AVIV, Israel and RALEIGH, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) --RedHill Biopharma Ltd.(Nasdaq:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its third-quarter 2020 financial results and business highlights on Thursday, November 12, 2020.

The Company will host a conference call and webcast onThursday,November12, 2020,at 8:30 a.m.EST, during which it will present key highlights for the third quarter of 2020, including:

To participate in the conference call, please dial one of the following numbers 15 minutes prior to the start of the call:United States: +1-877-870-9135; International: +1-646-741-3167and Israel:+972-3-530-8845;the access code for the call is:4549918.

About RedHill BiopharmaRedHill Biopharma Ltd. (Nasdaq:RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs,Movantik®for opioid-induced constipation in adults1,Talicia®for the treatment ofHelicobacter pylori (H. pylori)infection in adults2, andAemcolo®for the treatment of travelers’ diarrhea in adults3. RedHill’s key clinical late-stage development programs include: (i)RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (ii)opaganib(Yeliva®), a first-in-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii)RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (iv)RHB-102(Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v)RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is also being evaluated for COVID-19 and (vi)RHB-106, an encapsulated bowel preparation. More information about the Company is available atwww.redhillbio.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified,and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation,risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trialsor the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and numberand typeof additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidatesandTalicia®; (v) the Company’s ability to successfullycommercialize and promoteTalicia®,and Aemcolo®and Movantik®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidatesand the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii)theeffect of patients suffering adverse experiences using investigative drugs under theCompany's Expanded AccessProgram; (xiv) competition from othercompanies and technologies within the Company’s industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEConMarch4,2020. All forward-looking statements included in thispressrelease are made only as of the date of this press release.The Companyassumesno obligation to update any written or oral forward-looking statement, whether as a result of new information, future events orotherwiseunless required by law.

_________________________________________________

1Full prescribing information for Movantik®(naloxegol) is available at:www.Movantik.com.2Full prescribing information for Talicia®(omeprazole magnesium, amoxicillin and rifabutin) is available at:www.Talicia.com.3Full prescribing information for Aemcolo®(rifamycin) is available at:www.Aemcolo.com.